Alemtuzumab for aggressive relapsing-remitting MS and active secondary progressive MS

Real Time Neurology's Daniel Kantor, MD interviews Sam Hunter, MD, PhD about hope for people with Multiple Sclerosis and high disability and frequent relapses. Alemtuzumab is FDA approved for relapsing forms of MS, and Dr. Hunter discusses reversal of disability in people with aggressive relapsing-remitting MS and active secondary progressive MS (SPMS),